Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

First-ever oncology hospital-at-home program improves patient outcomes, reduces hospitalizations

Researchers at Huntsman Cancer Institute at the University of Utah (U of U) presented the first outcomes evaluation of an adult oncology hospital-at-home program today at the 2020 American Society of Clinical Oncology annual meeting.

29 May 2020

Clinical trial shows anti-tumor responses in metastatic castration-resistant prostate cancer patients

The preliminary results of a Phase I clinical trial conducted by researchers at the Yale Cancer Center have shown that ARV-110, an androgen receptor PROTAC protein degrader, demonstrates clinical evidence of anti-tumor responses in patients with metastatic castration-resistant prostate cancer (mCRPC) who have failed prior therapy.

29 May 2020

Monoclonal antibody therapy achieves modest reduction in recurrence for patients with HER2-positive DCIS

The addition of the monoclonal antibody therapy Trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma in situ (DCIS) on the NRG Oncology clinical trial NSABP B-43.

29 May 2020

Adoptive T-cell therapy targeting MAGE-A4 achieves responses in patients with multiple solid tumors

The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial sarcoma, head and neck cancer and lung cancer, according to results from a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

29 May 2020

Targeted therapy tepotinib shows durable response in NSCLC patients with METex14 skipping mutation

Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a study published today in the New England Journal of Medicine and presented at the 2020 American Society of Clinical Oncology Annual Meeting ASCO20 Virtual Meeting (Abstract 9556 - Poster 322) by researchers from The University of Texas MD Anderson Cancer Center.

29 May 2020

Targeted therapy pralsetinib shows high response rates in patients with RET fusion-positive cancers

The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the international Phase I/II ARROW trial, led by researchers at The University of Texas MD Anderson Cancer Center.

29 May 2020

Addition of monoclonal antibody to trimodality therapy offers no benefit in HER2 over expressing esophageal cancer

Results of the NRG Oncology clinical trial RTOG 1010 indicated that the addition of the monoclonal antibody trastuzumab to neoadjuvant trimodality treatment did not improve disease-free survival outcomes for patient with HER2 overexpressing local and locally advanced esophageal adenocarcinoma.

29 May 2020

Study analyzes cancer diagnosis in children with birth defects

Scientific studies suggest that children with birth defects are at increased risk of cancer. However, it has not been assessed whether the type of cancer, the age at which they are diagnosed or the extent of cancer spread at the time of diagnosis, is different for children with birth defects compared to children without birth defects.

29 May 2020

Researchers test new treatment protocol for lymphoma

Lymphoma is a type of blood cancer that develops from lymphocytes (a type of white blood cell). It has many subtypes.

29 May 2020

Scientist explore potential drugs to prevent cell resistance in different types of cancer

Cancer therapy may shrink the tumor of a patient, and the patient may feel better. But unseen on a CT scan or MR image, some of the cells are undergoing ominous changes.

29 May 2020

Combination therapy does not show superior efficacy in newly diagnosed myeloma

The combination of carfilzomib, lenalidomide, and dexamethasone (KRd) did not show superior efficacy in patients with newly diagnosed myeloma absent a high-risk disease prognosis, compared with the standard of care--bortezomib, lenalidomide, and dexamethasone (VRd).

29 May 2020

Targeted therapy shows immense benefit for patients with early stage NSCLC

According to findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery significantly improves disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations.

29 May 2020

Radiation and surgery do not prolong survival in newly diagnosed metastatic breast cancer

Up to now, women who present with a new diagnosis of breast cancer that is already in an advanced stage (stage IV) face an unanswered question about whether surgery and radiation to the tumor in the breast (local therapy) will prolong survival compared to the traditional treatment of systemic treatment alone.

29 May 2020

Ludwig Cancer Research study profiles immune landscape of brain tumors

A Ludwig Cancer Research study has profiled, in a sweeping comparative analysis, the distinct immune landscapes of tumors that arise in the brain, or gliomas, and those that metastasize to the organ from the lungs, breast and skin.

28 May 2020

Oncologists highlight the need for more palliative care training

Oncologists who practice and teach at the Johns Hopkins Kimmel Cancer Center are calling on medical oncology training programs to invest substantially more time educating physicians about palliative care and how to talk to patients about "bad news."

28 May 2020

Combination therapy found to be effective against IDH1-mutated acute myeloid leukemia

A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a Phase Ib/II trial led by researchers at The University of Texas MD Anderson Cancer Center.

28 May 2020

Inhibiting tumor signals can suppress the spread of cancer

For most people who die of cancer, the spread of the initial tumor is to blame. "Metastasis is what kills most cancer patients," says Serge Fuchs, a professor in Penn's School of Veterinary Medicine.

28 May 2020

CBD treatment improves arthritis symptoms in dogs, study finds

A team led by researchers at Baylor College of Medicine in collaboration with Medterra CBD conducted the first scientific studies to assess the potential therapeutic effects of cannabidiol for arthritic pain in dogs, and the results could lead the way to studying its effect in humans.

28 May 2020

New drug combinations could help overcome genetic immunotherapy resistance

A new study from researchers at the UCLA Jonsson Comprehensive Cancer Center helps explain how disruptions in genes can lead to the resistance to one of the leading immunotherapies, PD-1 blockade, and how new drug combinations could help overcome resistance to the anti-PD-1 therapy in a mechanistically-based way.

28 May 2020

Clinical study shows promising results for treatment of VHL disease-associated renal tumors

In an international trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with MK-6482, the small molecule inhibitor of hypoxia-inducible factor (HIF)-2a was well tolerated and resulted in clinical responses for patients with von Hippel-Lindau disease (VHL)–associated renal cell carcinoma.

28 May 2020

Oncology News and Research

Further Reading

First-ever oncology hospital-at-home program improves patient outcomes, reduces hospitalizations

Clinical trial shows anti-tumor responses in metastatic castration-resistant prostate cancer patients

Monoclonal antibody therapy achieves modest reduction in recurrence for patients with HER2-positive DCIS

Adoptive T-cell therapy targeting MAGE-A4 achieves responses in patients with multiple solid tumors

Targeted therapy tepotinib shows durable response in NSCLC patients with METex14 skipping mutation

Targeted therapy pralsetinib shows high response rates in patients with RET fusion-positive cancers

Addition of monoclonal antibody to trimodality therapy offers no benefit in HER2 over expressing esophageal cancer

Study analyzes cancer diagnosis in children with birth defects

Researchers test new treatment protocol for lymphoma

Scientist explore potential drugs to prevent cell resistance in different types of cancer

Combination therapy does not show superior efficacy in newly diagnosed myeloma

Targeted therapy shows immense benefit for patients with early stage NSCLC

Radiation and surgery do not prolong survival in newly diagnosed metastatic breast cancer

Ludwig Cancer Research study profiles immune landscape of brain tumors

Oncologists highlight the need for more palliative care training

Combination therapy found to be effective against IDH1-mutated acute myeloid leukemia

Inhibiting tumor signals can suppress the spread of cancer

CBD treatment improves arthritis symptoms in dogs, study finds

New drug combinations could help overcome genetic immunotherapy resistance

Clinical study shows promising results for treatment of VHL disease-associated renal tumors

Cancer Research - Second Edition eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News